Results 71 to 80 of about 4,641 (209)
Estimates of the duration of the early and late stage of gambiense sleeping sickness
Background: The durations of untreated stage 1 (early stage, haemo-lymphatic) and stage 2 (late stage, meningo-encephalitic) human African trypanosomiasis (sleeping sickness) due to Trypanosoma brucei gambiense are poorly quantified, but key to ...
Filipe, João AN +21 more
core +1 more source
Focus–specific clinical profiles in human African trypanosomiasis caused by Trypanosoma brucei rhodesiense [PDF]
<p><b>Background:</b> Diverse clinical features have been reported in human African trypanosomiasis (HAT) foci caused by <i>Trypanosoma brucei rhodesiense</i> (<i>T.b.rhodesiense</i>) giving rise to the ...
Odiit, Martin +18 more
core +1 more source
This study is aimed at evaluating the inclusion of miniature anion‐exchange centrifugation technique (mAECT) in the diagnosis and fexinidazole as treatment of gHAT in Central African Republic (CAR) after capacity building. A cross‐sectional pilot study was conducted during a mass diagnostic campaign from 16 September to 22 October 2022 in Nola‐Bilolo ...
Pierre-Marie Douzima +5 more
wiley +1 more source
Prevalence and under-detection of gambiense human African trypanosomiasis during mass screening sessions in Uganda and Sudan [PDF]
BACKGROUND: Active case detection through mass community screening is a major control strategy against human African trypanosomiasis (HAT, sleeping sickness) caused by T. brucei gambiense.
Haydon Daniel T +17 more
core +1 more source
The quantitative proteomics data here reported are part of a research article entitled “Increased acute immune response during the meningo-encephalitic stage of Trypanosoma brucei rhodesiense sleeping sickness compared to Trypanosoma brucei gambiense ...
Natalia Tiberti, Jean-Charles Sanchez
doaj +1 more source
Trypanosoma brucei CYP51: Essentiality and Targeting Therapy in an Experimental Model. [PDF]
Trypanosoma brucei gambiense is the main causative agent of Human African Trypanosomiasis (HAT), also known as sleeping sickness. Because of limited alternatives and treatment toxicities, new therapeutic options are urgently needed for patients with HAT.
Frédéric-Antoine Dauchy +8 more
doaj +1 more source
It is well known that several anti-trypanosomatid drugs accumulate in the parasite's mitochondrion, where they often bind to the organellar DNA, the kinetoplast.
Schnaufer, Achim; id_orcid +1 more
core +1 more source
The challenge of Trypanosoma brucei gambiense sleeping sickness diagnosis outside Africa [PDF]
Sleeping sickness is a lethal African disease caused by parasites of the Trypanosoma brucei subspecies, which is transmitted by tsetse flies. Occasionally, patients are reported outside Africa. Diagnosis of such imported cases can be problematic when the infection is due to Trypanosoma brucei gambiense, the chronic form of sleeping sickness found in ...
Lejon, V. +4 more
openaire +3 more sources
A major genetic locus in Trypanosoma brucei is a determinant of host pathology [PDF]
The progression and variation of pathology during infections can be due to components from both host or pathogen, and/or the interaction between them. The influence of host genetic variation on disease pathology during infections with trypanosomes has ...
C. Michael R. Turner +25 more
core +1 more source
P-type transport ATPases in Leishmania and Trypanosoma
P-type ATPases are critical to the maintenance and regulation of cellular ion homeostasis and membrane lipid asymmetry due to their ability to move ions and phospholipids against a concentration gradient by utilizing the energy of ATP hydrolysis.
Meade John C.
doaj +1 more source

